Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review.
Carreira H, Williams R, Müller M, Harewood R, Stanway S, Bhaskaran K. · 2018
Read Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review. by Carreira H, Williams R, Müller M, Harewood R, Stanway S, Bhaskaran K. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6292797.txt.
Introduction
Carreira and co-authors review mental health outcomes in breast cancer survivors. Their systematic review appeared in JNCI, the Journal of the National Cancer Institute. It compared women at least a year past breast cancer with women who never had cancer. The team searched four databases and tracked citations. Two reviewers picked studies, pulled data, and judged bias.
Sixty studies met the bar for inclusion. Most work on depression found higher rates in survivors. The same pattern held for anxiety in most studies. Survivors also showed more sleep problems and sexual problems. Memory and thinking problems were more common too. The authors see strong proof of added risk. They call for care plans that prevent and treat these harms.
Catalog record
| CREATOR | Carreira H, Williams R, Müller M, Harewood R, Stanway S, Bhaskaran K. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review By Helena Carreira, Rachael Williams, Martin Müller, Rhea Harewood, Susannah Stanway, Krishnan Bhaskaran Published in: JNCI Journal of the National Cancer Institute DOI: 10.1093/jnci/djy177 ABSTRACT Abstract Background We aimed to systematically review the evidence on adverse mental health outcomes in breast cancer survivors (≥1 year) compared with women with no history of cancer. Methods Studies were identified by searching MEDLINE, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature, and the Social Sciences Citation Index, and through backward citation tracking. Two researchers selected the studies, extracted data, and assessed the risk of bias. Results Sixty studies were included. Of 38 studies of depression, 33 observed more depression in breast cancer survivors; this was statistically significant in 19 studies overall, including six of seven where depression was ascertained clinically, three of four studies of antidepressants, and 13 of 31 that quantified depressive symptoms. Of 21 studies of anxiety, 17 observed more anxiety in breast cancer survivors, statistically significant in 11 studies overall, including two of four with clinical/prescription-based outcomes, and in eight of 17 of anxiety symptoms. Breast cancer survivors also had statistically significantly increased symptoms/frequency of neurocognitive dysfunction (18 of 24 studies), sexual dysfunctions (5 of 6 studies), sleep disturbance (5 of 5 studies), stress-related disorders/PTSD (2 of 3 studies), suicide (2 of 2 studies), somatisation (2 of 2 studies), and bipolar and obsessive-compulsive disorders (1 of 1 study each). Studies were heterogeneous in terms of participants’ characteristics, time since diagnosis, ascertainment of outcomes, and measures reported. Approximately one-half of the studies were at high risk of selection bias and confounding by socio-economic status. Conclusions There is compelling evidence of an increased risk of anxiety, depression and suicide, and neurocognitive and sexual dysfunctions in breast cancer survivors compared with women with no prior cancer. This information can be used to support evidence-based prevention and management strategies. Further population-based and longitudinal research would help to better characterize these associations. Women with a history of breast cancer are the largest group of cancer survivors in high-income countries (1). In the United States alone, more than 2.9 million women were estimated in 2012 to be living with a previous diagnosis of breast cancer (2). By 2022, this number is estimated to approach 4 million (2). Similarly, in the United Kingdom, the number of women living beyond breast cancer is expected to surpass 1.5 million during the next 20 years (3). A diagnosis of breast cancer is often overwhelmingly distressing (4). Women frequently experience some combination of anger, anxiety, despair, helplessness, fear of death, and suicidal thoughts (5,6). Clinically relevant symptoms of anxiety and/or depression are common during the treatment period (7,8), when acute treatment side effects may restrict daily activities (9). High prevalence of depressive symptoms and anxiety have also been observed during survivorship (10,11), with one study finding depressive symptoms persisting for at least two years after diagnosis in one in five women (12). Other adverse mental health outcomes, such as sleep disturbance, have also been reported both during cancer treatment and afterwards (13). A substantial proportion of the breast cancer survivors experience long-term iatrogenic effects of treatment, including fatigue, persistent pain, lymphedema, vasomotor symptoms, and infertility, all of which may negatively affect quality of life and mental health (14). Other important psychological challenges in the long term can include difficulties in re-adapting to professional, social, and intimate relationships and coping with the uncertainty about the future (15). To our knowledge, no systematic review to date has summarized the evidence from studies comparing breast cancer survivors with a noncancer control group for a broad spectrum of adverse mental health outcomes. Therefore, the aim of this study was to identify and summarize the studies that have quantitatively compared mental health outcomes in breast cancer survivors (≥1 year) vs women who did not have cancer; we also assessed the quality of the evidence on this topic by applying objective quality assessment criteria. METHODS This review was registered in the International Prospective Register of Systematic Reviews (PROSPERO 2017: CRD42017056946) and followed the a priori methods outlined in the protocol (published elsewhere [16]). Results were reported in accordance with the guidance of the Preferred Reporting Items for Systematic review and Meta-Analysis (17). Outcomes The predefined outcomes of interest were anxiety disorders; bipolar and related disorders; disruptive, impulse control, and conduct disorders; feeding and eating disorders; mood disorders; neurocognitive disorders; neurotic disorders; personality disorders; schizophrenia spectrum and other psychotic disorders; sexual dysfunctions of psychological nature; sleep wake disorders; somatoform disorders; substance-related disorders (including alcoholism); and trauma- and stressor-related disorders. We also considered eligible the studies providing data on self-injurious behavior (including self-harm, suicide, and suicidal ideation). These categories were selected after systematically reviewing those listed in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (18) and in the ICD-10 Classification of Mental and Behavioural Disorder (19) to exclude conditions with usual onset during childhood or with strong genetic component (eg Huntington’s disease). The comprehensive list of outcomes was aimed at exploring what evidence was available on the topic without making strong assumptions as to whether the stress induced by the breast cancer diagnosis and treatment could trigger the condition. The outcomes of interest were disorders clinically diagnosed, but we also considered symptomatology evaluated with psychometric instruments. Data Sources and Identification Potentially eligible studies were identified in four databases: MEDLINE, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature, and the Social Sciences Citation Index. A search expression tailored for each database was created including terms for the exposure (breast cancer), outcomes (the predefined mental disorders), and comparators (eg, risk) (full MEDLINE search string provided in the Appendix [Supplementary Table 1, available online]). Results retrieved from the inception of the databases up to November 1, 2017 were considered for this study. Two authors screened the list of references by applying the same inclusion and exclusion criteria to determine each study’s eligibility. The bibliographic references of eligible studies were manually screened to detect additional studies. Study Eligibility We considered as eligible observational studies that provided original data comparing the prevalence, incidence, or odds/hazard of at least one of the predefined lists of mental health outcomes (see above), clinically diagnosed or their symptomatology assessed through validated instruments, between adult female breast cancer survivors and a comparison group of women with no prior cancer. Female breast cancer survivors were defined as women with a history of breast cancer or in situ tumor for one year or longer. Studies with patients diagnosed with breast carcinomas in situ were included because despite of their excellent prognosis (20), they receive similar treatment to invasive breast cancers (21), and patients often experience substantial psychological distress both during and after the treatment period (22,23). Studies with no control group but reporting standardized incidence ratios were also eligible if the standardization was against a general female population. Studies that used psychometric instruments that had been altered from the standard/validated version were excluded, except where the alteration was limited to omission of questions that would not apply to the population under study. Studies including women who were institutionalized, under active treatment for breast cancer (excluding endocrine therapy), or who were specifically